BCL2L2

Bcl-2-like protein 2

21,355 patent compounds predicted against BCL2L2, 17,613 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1112346	0.60	9/20
SCHEMBL1112349	0.60	9/20
SCHEMBL1111901	0.70	8/20
SCHEMBL1111904	0.70	8/20
SCHEMBL1111890	0.69	8/20
SCHEMBL1111894	0.69	8/20
SCHEMBL158040	0.73	7/20
SCHEMBL158041	0.73	7/20
SCHEMBL553976	0.55	7/20
SCHEMBL553977	0.55	7/20
SCHEMBL1111796	0.45	7/20
SCHEMBL1112404	0.74	6/20
SCHEMBL1112407	0.74	6/20
SCHEMBL1111891	0.72	6/20
SCHEMBL1111895	0.72	6/20
SCHEMBL555322	0.68	6/20
SCHEMBL555323	0.68	6/20
SCHEMBL431063	0.57	6/20
SCHEMBL431064	0.57	6/20
SCHEMBL1111911	1.00	5/20

Germline variants in BCL2L2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BCL2L2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BCL2L2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	PHASE3	COMPLETED
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)	PHASE3	UNKNOWN
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia	PHASE3	COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	PHASE2	COMPLETED
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	PHASE2	RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL	PHASE2	RECRUITING
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL	PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission	PHASE2	ACTIVE_NOT_RECRUITING
Combination Immunotherapy Targeting Melanoma	PHASE1/PHASE2	RECRUITING
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML	PHASE2	ACTIVE_NOT_RECRUITING
SPC2996 in Chronic Lymphocytic Leukaemia	PHASE1/PHASE2	COMPLETED
Ibrutinib + Venetoclax in Untreated WM	PHASE2	ACTIVE_NOT_RECRUITING
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia	PHASE2	COMPLETED
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia	PHASE2	ACTIVE_NOT_RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	PHASE1	COMPLETED
Safe Accelerated Venetoclax Escalation in CLL	PHASE1	ACTIVE_NOT_RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	PHASE1	ACTIVE_NOT_RECRUITING
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases	PHASE1	COMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue	nan	COMPLETED
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer	nan	COMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia	nan	COMPLETED
Smoking Influence on Apoptosis in Periodontitis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BCL2L2 binder may also engage these)

Protein	Name	Similarity
Q1RMX3	—	1.000	Q1RMX3 →
Q45T69	—	1.000	Q45T69 →
P70345	—	1.000	P70345 →
Q90ZN1	—	0.987	Q90ZN1 →
Q07816	—	0.983	Q07816 →
Q91828	—	0.983	Q91828 →
BAX	Apoptosis regulator BAX	0.982	landscape →
Q90343	—	0.982	Q90343 →
O02703	—	0.979	O02703 →
Q07813	—	0.977	Q07813 →
Q91827	—	0.977	Q91827 →
O08734	—	0.977	O08734 →
Q63690	—	0.976	Q63690 →
BCL2L1	Bcl-2-like protein 1	0.975	landscape →
Q08DK0	—	0.974	Q08DK0 →
Q9H3Z7	—	0.974	Q9H3Z7 →
O77737	—	0.974	O77737 →
Q9CR25	—	0.973	Q9CR25 →
O75064	—	0.973	O75064 →
Q64373	—	0.973	Q64373 →
Q9BVI4	—	0.973	Q9BVI4 →
P10937	—	0.972	P10937 →
Q1JQC5	—	0.972	Q1JQC5 →
P53563	—	0.972	P53563 →
Q002B5	—	0.971	Q002B5 →
Q8VDP3	—	0.971	Q8VDP3 →
Q8TE68	—	0.971	Q8TE68 →
A0AVI4	—	0.971	A0AVI4 →
BCL2L10	Bcl-2-like protein 10	0.970	landscape →
Q8R5F8	—	0.970	Q8R5F8 →